Limits...
The role of VipAlbumin(®) as an immunostimulatory agent for controlling homeostasis and proliferation of lymphoid cells.

Dwijayanti DR, Djati MS, Rifa'I M - Cent Eur J Immunol (2016)

Bottom Line: The concentrations of VipAlbumin (®) used were 0 µg/ml; 0.33 µg/ml; 33.3 µg/ml; and 3333.3 µg/ml.VipAlbumin can significantly increase the relative number of CD4(+)CD62L(+) T cell, regulatory T cell, and B220+ cell (p < 0.05) compared to control.This study gives scientific evidence that VipAlbumin can be used as an immunostimulant which accelerates immunocompetent cells growth.

View Article: PubMed Central - PubMed

Affiliation: Biology Department, Brawijaya University, Malang, Indonesia.

ABSTRACT
VipAlbumin(®) is a supplement from snakehead fish (Ophiocephalus striatus) which has high content of albumin that is very important to develop new cells. The aims of this study were to know the effect of VipAlbumin(®) to cell proliferation, expression level of CD4(+)CD62L(+) T cell, regulatory T cell, and B220+ cell, and immunocompetent cell cycle. Cell isolated from spleen of pathogen free mice were cultured in RPMI 1640 with 10% FBS, 1% Pen/Strep 10×, 2-Mercaptoetanol, anti-CD3 and LPS. The concentrations of VipAlbumin (®) used were 0 µg/ml; 0.33 µg/ml; 33.3 µg/ml; and 3333.3 µg/ml. The cell was incubated in CO2 5% incubator 37°C for 3 days for cell cycle and 5 days for proliferation analysis and cell expression. FACS analysis was done to know cell proliferation profile, status of cell, and cell cycle. Concentration 33.3 µg/ml and 3333.3 µg/ml significantly can increase cell proliferation and induce cell enter G2/M phase (p < 0.05) compared to control. VipAlbumin can significantly increase the relative number of CD4(+)CD62L(+) T cell, regulatory T cell, and B220+ cell (p < 0.05) compared to control. This study gives scientific evidence that VipAlbumin can be used as an immunostimulant which accelerates immunocompetent cells growth.

No MeSH data available.


Related in: MedlinePlus

Stimulation cells from spleen by using VipAlbumin® for 5 days showed the increase of B220+ cell relative number. Spleen cells were cultured in RPMI medium with 10% FBS, anti-CD3 and LPS for five days. On day 5, cell cultures were harvested and analyzed by flow cytometry and tabulated into Microsoft Excel. B220+ cell were presented in relative number and obtained from all lymphocyte cells population. Data were mean ± SD in each group with p value ≤0.05
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4829819&req=5

Figure 0004: Stimulation cells from spleen by using VipAlbumin® for 5 days showed the increase of B220+ cell relative number. Spleen cells were cultured in RPMI medium with 10% FBS, anti-CD3 and LPS for five days. On day 5, cell cultures were harvested and analyzed by flow cytometry and tabulated into Microsoft Excel. B220+ cell were presented in relative number and obtained from all lymphocyte cells population. Data were mean ± SD in each group with p value ≤0.05

Mentions: Because of VipAlbumin® ability in increasing immunocompetent cell proliferation, we investigated its immunostimulant activity through expression level of naïve T cells (CD4+CD62L+), regulatory T cells (CD4+CD25+CD62L+), and B lymphocyte cells (B220+). Figure 2 proved that D2 and D3 of VipAlbumin® specifically increased the number of CD4+CD62L+ T cells became 81.85% and 78.71% (p < 0.05) compared to control (68.37%) treatment. Among D1, D2, and D3 of VipAlbumin® could increase the relative number of regulatory T cells (Treg) (Fig. 3) from 64.5% in control treatment became 71.15% (D1), 68.67% (D2), and 67.58% (D3) significantly different (p < 0.05). VipAlbumin® not only could increase the expression level of T lymphocyte cells but also B lymphocyte cells (B220+). This statement was showed in Fig. 4. The expression levels of B220+ cells in control treatment was 51.44% and increased became 54.09% in D1 treatment, 57.10% in D2 treatment, and 64.57% in D3 treatment. T lymphocyte cells play a role in cellular immune response whereas B lymphocyte cells played a role in humoral immune response which functioned as extracellular protection. This result proved that VipAlbumin® might have a function to activate both cellular and humoral immune system.


The role of VipAlbumin(®) as an immunostimulatory agent for controlling homeostasis and proliferation of lymphoid cells.

Dwijayanti DR, Djati MS, Rifa'I M - Cent Eur J Immunol (2016)

Stimulation cells from spleen by using VipAlbumin® for 5 days showed the increase of B220+ cell relative number. Spleen cells were cultured in RPMI medium with 10% FBS, anti-CD3 and LPS for five days. On day 5, cell cultures were harvested and analyzed by flow cytometry and tabulated into Microsoft Excel. B220+ cell were presented in relative number and obtained from all lymphocyte cells population. Data were mean ± SD in each group with p value ≤0.05
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4829819&req=5

Figure 0004: Stimulation cells from spleen by using VipAlbumin® for 5 days showed the increase of B220+ cell relative number. Spleen cells were cultured in RPMI medium with 10% FBS, anti-CD3 and LPS for five days. On day 5, cell cultures were harvested and analyzed by flow cytometry and tabulated into Microsoft Excel. B220+ cell were presented in relative number and obtained from all lymphocyte cells population. Data were mean ± SD in each group with p value ≤0.05
Mentions: Because of VipAlbumin® ability in increasing immunocompetent cell proliferation, we investigated its immunostimulant activity through expression level of naïve T cells (CD4+CD62L+), regulatory T cells (CD4+CD25+CD62L+), and B lymphocyte cells (B220+). Figure 2 proved that D2 and D3 of VipAlbumin® specifically increased the number of CD4+CD62L+ T cells became 81.85% and 78.71% (p < 0.05) compared to control (68.37%) treatment. Among D1, D2, and D3 of VipAlbumin® could increase the relative number of regulatory T cells (Treg) (Fig. 3) from 64.5% in control treatment became 71.15% (D1), 68.67% (D2), and 67.58% (D3) significantly different (p < 0.05). VipAlbumin® not only could increase the expression level of T lymphocyte cells but also B lymphocyte cells (B220+). This statement was showed in Fig. 4. The expression levels of B220+ cells in control treatment was 51.44% and increased became 54.09% in D1 treatment, 57.10% in D2 treatment, and 64.57% in D3 treatment. T lymphocyte cells play a role in cellular immune response whereas B lymphocyte cells played a role in humoral immune response which functioned as extracellular protection. This result proved that VipAlbumin® might have a function to activate both cellular and humoral immune system.

Bottom Line: The concentrations of VipAlbumin (®) used were 0 µg/ml; 0.33 µg/ml; 33.3 µg/ml; and 3333.3 µg/ml.VipAlbumin can significantly increase the relative number of CD4(+)CD62L(+) T cell, regulatory T cell, and B220+ cell (p < 0.05) compared to control.This study gives scientific evidence that VipAlbumin can be used as an immunostimulant which accelerates immunocompetent cells growth.

View Article: PubMed Central - PubMed

Affiliation: Biology Department, Brawijaya University, Malang, Indonesia.

ABSTRACT
VipAlbumin(®) is a supplement from snakehead fish (Ophiocephalus striatus) which has high content of albumin that is very important to develop new cells. The aims of this study were to know the effect of VipAlbumin(®) to cell proliferation, expression level of CD4(+)CD62L(+) T cell, regulatory T cell, and B220+ cell, and immunocompetent cell cycle. Cell isolated from spleen of pathogen free mice were cultured in RPMI 1640 with 10% FBS, 1% Pen/Strep 10×, 2-Mercaptoetanol, anti-CD3 and LPS. The concentrations of VipAlbumin (®) used were 0 µg/ml; 0.33 µg/ml; 33.3 µg/ml; and 3333.3 µg/ml. The cell was incubated in CO2 5% incubator 37°C for 3 days for cell cycle and 5 days for proliferation analysis and cell expression. FACS analysis was done to know cell proliferation profile, status of cell, and cell cycle. Concentration 33.3 µg/ml and 3333.3 µg/ml significantly can increase cell proliferation and induce cell enter G2/M phase (p < 0.05) compared to control. VipAlbumin can significantly increase the relative number of CD4(+)CD62L(+) T cell, regulatory T cell, and B220+ cell (p < 0.05) compared to control. This study gives scientific evidence that VipAlbumin can be used as an immunostimulant which accelerates immunocompetent cells growth.

No MeSH data available.


Related in: MedlinePlus